Sophia Genetics and Hitachi announce collaboration

Hitachi plans to broaden its healthcare business, leveraging the strengths of in-vitro diagnostics systems, particle therapy treatment systems and digital technologies

Sophia Genetics and Hitachi have entered into a long-term collaboration agreement aimed to bring clinical, genomic and real-world insights to healthcare providers, pharmaceutical and biopharmaceutical companies. Under the agreement, the two companies will collaboratively expand and develop Hitachi’s digital healthcare solutions and the Sophia DDM platform.

The Sophia DDM Platform is a cloud-based software-as-a-service analytics platform that uses AI and machine learning to generate actionable insights for clinicians and researchers from complex datasets.

The companies have reportedly identified multiple areas for potential collaboration including secure personal genomics data management, deployment of data and insights for better healthcare decisions and acceleration of drug development in oncology and other disease areas.

Initially, the companies will focus on leveraging genomics, clinical data analytics and AI to expand the commercialisation of the Sophia DDM Platform and Hitachi’s digital healthcare solutions, like its molecular tumour board support service. Over the long term however, the two companies will also collaborate on R&D related product development.

"Sophia Genetics is a leader in precision medicine,” said Keiji Kojima, Executive VP and Executive Officer, and General Manager of Smart Life Business Management Division of Hitachi. “Hitachi is excited to start long term partnership with Sophia Genetics to co-create innovative solutions for improving quality of life of patients by leveraging both companies’ data analytics and AI technologies.”

“At Sophia Genetics, we are committed to improving patient outcomes through data driven medicine and we are excited to collaborate with Hitachi, a global leader in real-world evidence and multimodal clinical decision support, who shares these values,” said Jurgi Camblong, CEO and Founder of Sophia Genetics.